Forty-six consecutive @entity1 with @entity2506 were treated with @entity3524 ( @entity3525 ). Ages ranged from 1-79 years: 29 adults, six adolescents, six @entity1 and five @entity1 . Underlying diseases were found in 38 @entity1 (82.6%). Twenty-six @entity1 (56.5%) were admitted in @entity772 . All isolates were sensitive to @entity3525 , with MICs for 12 strains ranging from 0.01 to 0.08 mg/l. @entity3525 was used as single-drug therapy for 12 to 27 days-mean 15 days. The daily dose of @entity3525 was 200 mg/kg, in four or six equal intravenous doses. @entity3525 penetration into the CSF was studied in four @entity1 . 40 @entity1 (87.0%) were cured. The mortality rate was 13.0%. All dead @entity1 had been admitted in @entity772 . The mortality rate in @entity772 @entity1 was 23.1%. CSF sterilization was obtained within 72 h after starting treatment, mostly (90.7%) in the first 48 h. No serious side-effects were observed. The study proves that @entity3525 is a safe and very successful therapy for @entity2506 .

Cefotaxime in XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants'] @entity3525 :: ('CHEBI:36467', 'Chemical') :: ['CTX'] @entity2506 :: ('MESH:D008586', 'Disease') :: ['pneumococcal meningitis'] @entity772 :: ('MESH:D003128', 'Disease') :: ['coma', 'comatose'] @entity3524 :: ('MESH:D002439', 'Chemical') :: ['cefotaxime']
@entity2506 :: (MESH:D008586,Disease) :: ['pneumococcal meningitis']
